Abstract: OBJECTIVE To evaluate the effects of ursodeoxycholic acid (UDCA) for pregnancy outcomes of intrahepatic cholestasis of pregnancy. METHODS The Pubmed, Medline, CNKI, VIP and Wan Fang databases were searched to retrieve randomized controlled trials assessing the pregnancy outcomes of UDCA versus control therapy in the treatment of ICP. Meta-analysis was performed by Stata 12.0. RESULTS Twelve studies involving 664 patients were included. The result of meta-analysis showed that:①UDCA was superior to s-adenosyl-methionine on the reduction in total prematurityRR=0.49, 95%CI=0.28~0.84, P=0.01 and fetal distressRR=0.45, 95%CI=0.20~0.99, P=0.04, but there was no significant difference in the presence of meconium, caesarean section rate, apgar score<7 at 5 min and hospitalization in neonatal intensive care unit. ②UDCA was superior to placebo on the reduction in total prematurityRR=0.50, 95%CI=0.34~0.73, P=0.000 1, fetal distressRR=0.52, 95%CI=0.29~0.94, P=0.02, apgar score<7 at 5 minRR=0.26, 95%CI=0.10~0.69, P=0.006 and hospitalization in neonatal intensive care unitRR=0.39, 95%CI=0.17~0.88, P=0.02, but there was no significant difference in the presence of meconium and caesarean section rate. ③UDCA was superior to cholestyramine on the reduction in total prematurityRR=0.50, 95%CI=0.27~0.94, P=0.03. ④There was no significant difference on improving the pregnancy outcomes between UDCA and dexamethasone. CONCLUSION UDCA is effective for improving the pregnancy outcomes.